Bionomics upbeat despite bigger annual loss
05 September, 2003 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has reported an after-tax loss of $4.54 million for the year to June 30, up from $3.49 million in 2001-02.
Monash launches new brain research centre
05 September, 2003 by Melissa TrudingerMonash University yesterday launched its new Centre for Brain and Behaviour, bringing together more than 150 researchers including students and postdocs from 21 university departments and research centres.
Eiffel signs US insulin trial deal
05 September, 2003 by Graeme O'NeillMelbourne drug re-engineering company Eiffel Technologies (ASX:EIF) has signed an agreement with a large US drug-delivery company to trial an inhalable form of insulin produced by Eiffel's proprietary supercritical fluid technology.
Arthritis CRC picks up new funding and partners
03 September, 2003 by Melissa TrudingerThe Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs.
AustCancer finds cancer jammer molecule
02 September, 2003 by Graeme O'NeillPerth-based cancer therapeutics developer Australian Cancer Technology's (ASX:ACU) joint discovery project with Cambridge-based BioFocus (AIM:BIO) has designed a tiny spanner to jam the molecular works of cancer cells that evade conventional chemotherapy and radiotherapy.
Hunt for SARS source far from over: researcher
02 September, 2003 by Graeme O'NeillVirologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified.
Qld's Élan joins with US Meditech on biohazard
01 September, 2003 by Melissa TrudingerQueensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax.
New virus linked to breast cancer
22 August, 2003 by Jeremy TorrResearchers at the Prince of Wales Hospital have established a link between breast cancer and the human form of a mouse virus.
Novogen scores new US patent
19 August, 2003 by Jeremy TorrBiopharma Novogen has been granted a US patent for isoflavone treatment for fibroids and endometriosis specific to women.
Victor Chang Institute to work with BioDiem
19 August, 2003 by Jeremy TorrSydney's Victor Chang Cardiac Research Institute has signed a deal to investigate a tissue restorative agent, BDM-K, for Melbourne biopharma BioDiem
Watch for new wave of mad cow: Masters
15 August, 2003 by Melissa TrudingerWhile the incidence of variant Creutzfeldt-Jakob disease (vCJD) -- the human form of mad cow disease -- appears to have slowed in the UK after 146 confirmed cases since the epidemic began in the mid-1990's, a new wave of cases could be waiting in the wings, according to Australian neuroscientist Prof Colin Masters.
AustCancer shuffles staff and direction
14 August, 2003 by Jeremy TorrAustralian Cancer Technology (AustCancer) has changed tack with new management, a new product line and a move from Perth to Sydney -- all in one day.
Neuro facility teams with UK firm to develop MND model
12 August, 2003 by Melissa TrudingerA commercial alliance has been formed between the National Neuroscience Facility (NNF) and UK company Danio Labs, to develop a zebrafish model for Motor Neurone Disease (MND) and other neurodegenerative diseases.
Cytopia to use Start grant in pulmonary disorder work
06 August, 2003 by Graeme O'NeillMelbourne biomedical company Cytopia has won a $1.7 million AusIndustry Start grant to develop treatments for chronic obstructive pulmonary disorder (COPD), a currently untreatable condition that affects more than 600 million people worldwide.
Metabolic to spend $2.1m grant on clinical trials
06 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) has been granted an R&D Start grant of up to AUD$2.1 million to conduct its Phase IIb clinical trial for its obesity drug AOD9604.
